Key result
ApoE ε4 carriage linked to ~1.9-point lower 3-month MoCA scores in older ICAS patients.
Why the study?
The association between apolipoprotein E (ApoE) ε4 carrier status and 3-month cognitive performance and structural brain injury in older patients with intracranial atherosclerotic stenosis (ICAS) required investigation.
Is Apolipoprotein E (ApoE) ε4 carrier status associated with poorer 3-month cognitive performance and increased white matter hyperintensity burden in patients aged ≥60 years with intracranial atherosclerotic stenosis?
Cohort (n=150)
No
Is Apolipoprotein E (ApoE) ε4 carrier status associated with poorer 3-month cognitive performance and increased white matter hyperintensity burden in patients aged ≥60 years with intracranial atherosclerotic stenosis?
In older patients with intracranial atherosclerotic stenosis, ApoE ε4 carriage is associated with worse 3-month cognitive performance (MoCA and MMSE) and greater white matter hyperintensity burden.
Answers are grounded in this paper and cite their sources.
ApoE ε4 may warrant closer cognitive surveillance in older ICAS patients; leaves open whether genotyping extends risk models or should alter management.
Objectives To investigate whether apolipoprotein E (ApoE) ε4 carrier status is associated with 3-month cognitive performance and structural brain injury in older patients with intracranial atherosclerotic stenosis (ICAS).Methods This prospective cohort study enrolled 150 patients aged ≥60 years with ICAS (≥50% stenosis on MRA/CTA). ApoE ε4 carriers (n = 21, 14.0%) were compared with noncarriers. Primary outcome was 3-month Montreal Cognitive Assessment (MoCA) score. Secondary cognitive outcome was 3-month Mini-Mental State Examination (MMSE) score. White matter hyperintensity burden defined as Fazekas score ≥2 was primary structural outcome. Multivariable linear and logistic regression models adjusted for age, sex, education, symptomatic ICAS, hypertension, and diabetes. Firth’s penalized logistic regression addressed near-complete separation in the Fazekas analysis. Results ApoE ε4 carrier status was associated with lower 3-month MoCA (β = -1.887, 95% CI: -3.359 to -0.415, P = 0.013) and MMSE scores (β = -1.931, 95% CI: -3.177 to -0.685, P = 0.003). The structural analysis yielded association with Fazekas score ≥2 (Firth OR = 6.144, 95% CI: 1.331 to 59.563, P = 0.017), although this estimate was imprecise and hypothesis-generating. Additional adjustment for baseline cognitive scores changed the cognitive estimates. Discussion In older patients with ICAS, ApoE ε4 carriage is associated with poorer 3-month global cognitive performance. Given the modest sample size, few ε4 carriers, short follow-up, and single-center design, larger multicenter studies with longer follow-up are needed to clarify the longitudinal relationship between ApoE ε4 status and cognitive change.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) conducted a cohort in Intracranial atherosclerotic stenosis (ICAS) (n=150). Apolipoprotein E (ApoE) ε4 carrier status vs. ApoE ε4 noncarriers was evaluated on 3-month Montreal Cognitive Assessment (MoCA) score (β -1.887, 95% CI -3.359 to -0.415, p=0.013). ApoE ε4 carrier status was associated with lower 3-month MoCA scores in older ICAS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: